Grades severity of nephritis secondary to immune checkpoint inhibitor (ICPi) therapy based on Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 criteria. This standardized grading system evaluates serum creatinine levels, renal function changes, and clinical symptoms to determine the severity of immune-mediated nephritis and guide clinical management decisions including ICPi therapy continuation, corticosteroid treatment, nephrology consultation needs, and monitoring for life-threatening renal complications. ICPi-induced nephritis has an incidence of 1-2% in single-agent therapy and 4.5% in combination therapy, with median onset at 14 weeks (range 6.5-21 weeks). The calculator provides evidence-based management recommendations essential for oncologists, nephrologists, and multidisciplinary teams managing patients on immunotherapy.
Awaiting Clinical Input
Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.
The Immune-Related Adverse Events for Renal Toxicities - Nephritis is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within oncology.
Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.
Mild - Creatinine 1.5-2× baseline
Moderate - Creatinine 2-3× baseline
Severe - Creatinine >3-6× baseline
Life-threatening - Creatinine >6× baseline OR dialysis required
Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.
Open in Web AppClinical Decision Support (CDS) Notice & Legal Disclaimer
This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.